Leerink Partnrs Has Negative View of AstraZeneca Q4 Earnings

AstraZeneca PLC (NASDAQ:AZN) – Equities research analysts at Leerink Partnrs dropped their Q4 2024 EPS estimates for AstraZeneca in a research report issued on Monday, October 28th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of $1.05 for the quarter, down from their previous forecast of $1.06. The consensus estimate for AstraZeneca’s current full-year earnings is $4.07 per share. Leerink Partnrs also issued estimates for AstraZeneca’s FY2026 earnings at $5.99 EPS.

A number of other equities research analysts have also recently weighed in on AZN. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen upped their target price on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Trading Down 3.2 %

Shares of AZN opened at $72.83 on Tuesday. AstraZeneca has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $225.82 billion, a P/E ratio of 35.18, a PEG ratio of 1.39 and a beta of 0.46. The firm’s 50-day moving average is $79.77 and its two-hundred day moving average is $78.64.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Brookstone Capital Management purchased a new stake in shares of AstraZeneca during the first quarter worth about $315,000. Wealthcare Advisory Partners LLC grew its stake in AstraZeneca by 9.7% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock worth $416,000 after acquiring an additional 543 shares during the period. Diversified Trust Co raised its holdings in AstraZeneca by 5.8% in the 1st quarter. Diversified Trust Co now owns 4,343 shares of the company’s stock valued at $294,000 after acquiring an additional 238 shares during the last quarter. Miracle Mile Advisors LLC lifted its stake in shares of AstraZeneca by 8.1% during the 1st quarter. Miracle Mile Advisors LLC now owns 7,614 shares of the company’s stock worth $516,000 after purchasing an additional 572 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of AstraZeneca by 172.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 10,496 shares of the company’s stock worth $711,000 after purchasing an additional 6,650 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.